Skip to main content
. 2022 Dec 8;131:106316. doi: 10.1016/j.bioorg.2022.106316

Fig. 3.

Fig. 3

(A) Dose-response curves and EC50 of BA-1 on inhibiting the entry of SARS-CoV-2 PsV and VSV-G in 293 T-ACE2 cells. (B) Evaluation on cytotoxicity of BA-1 in 293 T. (C) BA-1 inhibited pSARS-CoV-2 infection by dose-dependent blocking of S-mediated membrane fusion.